DNA Q1 2022 Earnings — Ginkgo Bioworks Holdings, Inc. Revenue & Financial Results | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

$418M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$168M+281.9% YoY

Gross Profit

$83M49.3% margin

Operating Income

-$675M-401.0% margin

Net Income

-$591M-350.6% margin

EPS (Diluted)

$-14.80

QoQ Revenue Growth

+13.4%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$23M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$444M

Stockholders' Equity

$1.6B

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$168M	$44M	+281.9%
Gross Profit	$83M	$20M	+306.8%
Operating Income	-$675M	-$57M	-1082.5%
Net Income	-$591M	-$74M	-702.7%

Revenue Segments

Service

$133M79%

Foundry Revenue

$21M13%

Product

$14M8%